AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUL 4 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A new report in Experimental Biology and Medicine describes the potential for a vaccine against myasthenia gravis in humans, following its success against a similar disease in animals.
The peptide vaccine was most effective when conjugated to diphtheria toxin (DT) with alum as adjuvant and is now ready for trial in humans, reported J.L. McAnally and colleagues at the University of Alabama, Birmingham.
"Myasthenia gravis (MG) and its animal model, experimental autoimmune (EA) MG, are caused by interference with neuromuscular transmission by auto-antibodies against the nicotinic acetylcholine receptor (AChR) on muscle," explained McAnally and coworkers.
Their previous research had shown that two vaccines comprising peptide denoted RhCA 67-16 and RhCA 611-001 could prevent EAMG in rats by inducing anti-idiotypic/clonotypic antibodies (Ab) and lowering levels of AChR Ab.
The vaccines used in the rat studies had employed complete Freund's adjuvant (CFA) and keyhole limpet hemocyanin (KLH) as a carrier. Here, McAnally and team used DT as a carrier and incomplete Freund's adjuvant (IFA) or alum, which are approved for use in humans, with the RhCA 611-001 peptide.
The combination of alum as adjuvant and DT as carrier offered protection against EAMG that was comparable with that achieved with CFA and KLH, ...